Patent ID: 11866725
Assignee: NOVARTIS AG
Field: Biotechnology (Chemistry)
Classification: CPC C | IPC C

Claim 10:
11. The lentiviral transfer vector of claim 1, wherein said lentiviral transfer vector comprises:
(i) a CMV promoter comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 52,
(ii) an LTR R region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 53,
(iii) an LTR U5 region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 54,
(iv) a primer binding site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 55,
(v) a packaging signal comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 56,
(vi) a major splice donor site comprising the nucleic acid sequence of SEQ ID NO: 57, which is within said packaging signal,
(vii) a partial gag sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:58,
(viii) a partial env sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:60,
(ix) a Rev-response element comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 62,
(x) a partial env sequence comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO:64,
(xi) a splice acceptor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 65, which is within said partial env sequence of part (x),
(xii) a central polypurine tract comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 67, 92, or 93,
(xiii) a splice acceptor site comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 68 or 94, which is within said central polypurine tract,
(xiv) an EF1alpha promoter having at least 95% sequence identity to SEQ ID NO: 71 or 95,
(xv) a polynucleotide encoding an EGFP comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 76 and/or a transgene sequence,
(xvi) a PRE sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 78 or 79,
(xvii) a partial nef sequence comprising a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO:83,
(xviii) a dU3 sequence comprising a nucleic acid sequencing having at least 95% sequence identity to SEQ ID NO:84,
(xix) an LTR R region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 85, and
(xx) an LTR U5 region comprising a nucleic acid sequence having at least 95% identity to SEQ ID NO: 86.